Provides clinically actionable information for developing and optimizing device‑aided symptomatic treatments and access pathways, but offers limited mechanistic or disease‑modifying insight for therapeutic discovery.

Though focused on cardiac disease, the work links AMPK-driven bioenergetic and mitochondrial dysfunction to pathology and demonstrates metformin can reverse those defects, offering indirect mechanistic and repurposing insight for Parkinson's strategies that target AMPK, mitochondrial/metabolic…

Clinically useful for therapeutic decision-making and risk mitigation in PD (monitoring, prescribing choices, and need for alternative strategies), but provides limited mechanistic or biomarker insights to directly drive novel drug discovery.

While this study has low direct value for therapeutic discovery, it identifies gaps in patient-facing exercise guidance that are important for improving dissemination, adherence to rehabilitation protocols, and ultimately the implementation of evidence-based nonpharmacologic interventions.

Offers a translationally relevant, infection-driven platform to study inflammation-mediated PD mechanisms and to test anti-inflammatory/antiviral or neuroprotective interventions, though its value hinges on how well it reproduces key PD features (e.g., alpha-synuclein aggregation, progressive…

This paper nominates klotho as a mechanistically supported, targetable modifier of PD-related cognitive decline (with a genetic biomarker KL-VS) by linking α-synuclein clearance, synaptic/NMDAR modulation, and microglial activity—making klotho-based therapies and biomarker-guided strategies…

Presents a tangible preclinical lead — a small-molecule Nrf2 activator with in vitro and in vivo efficacy in PD models — that targets oxidative stress/neuroinflammation and merits further PK, safety, and translational evaluation.

By implicating PI3K/AKT-dependent microglia–astrocyte crosstalk in toxin-induced dopaminergic degeneration, the work points to a targetable inflammatory mechanism (and potential PI3K-modulating interventions) relevant to PD therapeutic development.

Supports targeting NLRP3/NF-κB-driven neuroinflammation and oxidative stress as therapeutically relevant mechanisms in PD and highlights intranasal curcumin as a potentially translational repurposing/delivery strategy, though the study lacks motor, dopaminergic neuron, and pharmacokinetic endpoints.

The paper validates sensitive, noninvasive imaging biomarkers for detecting and tracking PD-like microstructural and neurochemical changes in vivo, useful for preclinical therapeutic monitoring and translational biomarker development despite offering limited new mechanistic or targetable insights.

Although not mechanistic, these clinically relevant findings support personalized levodopa dosing and integrated nutritional management to mitigate motor complications and inform clinical trial stratification and therapeutic optimization.

The work provides clinically relevant, subtype-specific imaging biomarkers of metabolism and DAT loss that can improve diagnostic stratification, patient selection and progression tracking in synucleinopathy trials—useful for translational studies though it does not directly identify targetable…

This study provides pragmatic, scalable evidence for improving a bothersome PD non-motor symptom and quality of life through behavioral/nursing care, but offers limited mechanistic or drug-discovery insights for therapeutic development.

While it offers little mechanistic or biomarker insight for therapy discovery, the paper is useful for therapeutic planning and trial design by clarifying evolving disease burden, subtype shifts (notably vascular parkinsonism), and demographic patterns that affect recruitment and resource…

May yield practical, low-cost evidence to guide cane prescription and improve mobility in PD patients, but offers limited mechanistic insight or direct therapeutic discovery value for disease-modifying strategies.

Although it offers no molecular targets, this robust phenotyping can improve PD trial endpoints, patient stratification, and the design of behavioral or circuit-targeted interventions focused on social motivation.

This work demonstrates a translational, targeted delivery platform that overcomes BBB, cell-specificity, and controlled-release barriers for α-synuclein degraders—addressing key obstacles for disease-modifying Parkinson's therapies, though efficacy and safety require further validation in…

Points to astrocytic LAG3 as an actionable, potentially repurposable target that links sleep loss to α-syn accumulation and PD progression, offering a translational avenue for patients with sleep disturbances pending human validation and safety assessment.

Points to IRF7 as a putative biomarker and actionable nexus linking mitochondrial dysfunction, ferroptosis, and exercise-mediated neuroprotection in PD—offering a novel target for therapeutic development though requiring in vivo and translational validation.

Defining prodromal synucleinopathy with CSF α-synuclein SAA provides a clinically and biologically specific cohort for early intervention trials, improving patient selection, stratification, and potential outcome measures for Parkinson's and DLB therapeutic development.